Toremifene is primarily used in the treatment of breast cancer, particularly in postmenopausal women with estrogen receptor-positive or unknown metastatic breast cancer. It functions as a selective estrogen receptor modulator (SERM), binding to estrogen receptors and blocking the effects of estrogen on breast tissue, which helps to inhibit the growth of cancer cells. In clinical practice, Toremifene is often prescribed as an alternative to tamoxifen, especially for patients who may not tolerate tamoxifen well. It is administered orally and is generally well-tolerated, with side effects being manageable in most cases. Beyond its primary use in breast cancer, Toremifene has also been explored for its potential in treating other estrogen-dependent conditions, although its application in these areas is less established. Ongoing research continues to investigate its efficacy and safety in broader therapeutic contexts.